logo-loader
viewFlex Pharma

Flex Pharma to prove technology can prevent cramping in ALS

William McVicar, President and CEO of Flex Pharma Inc (NASDAQ: FLKS) tells Proactive Investors at the BIO CEO Conference in New York, that Flex Pharma is shaping up to be an exciting year ahead.

McVicar says Flex Pharma will have clinical trials reading out in the Q1 as well as in Q3 in ALS, multiple sclerosis, and Charcot-Marie-Tooth disease. Flex Pharma will report Q4 and full year 2017 results on March 7, 2018.

Quick facts: Flex Pharma

Price: - -

NASDAQ:FLKS
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Nextleaf Prepares for Potential Pharmaceutical Participation...

Nextleaf Solutions (CSE:OIL-OTCQB: OILFF) CEO Paul Pedersen joined Steve Darling from Proactive in Toronto with news the company has been issued their 14th patent. This is a U.S. patent that covers a process for acetylating THC and subsequent refinement of the acetylated THC using salting-out...

2 hours, 1 minute ago

2 min read